靶向脂质组学揭示急性失代偿期肝硬化患者循环脂质介质的广泛变化
本研究采用液相色谱-串联质谱法检测急性失代偿期肝硬化患者(伴ACLF 119例、不伴ACLF 127例)及健康对照(18例)血浆脂质介质谱,并在191例患者中重复检测28天。
要点
- 血浆脂质介质谱在急性失代偿期肝硬化中广泛改变,16种与疾病状态显著相关。
- LTE4和12-HHT组成的指纹可区分ACLF与非ACLF患者。
- LTE4、LXA5和EKODE与短期死亡率相关,LXA5和EKODE与凝血及肝衰竭相关。
核心结论
- 急性失代偿期肝硬化患者血浆脂质介质谱与疾病严重程度和预后相关。
- LTE4和12-HHT可区分ACLF与非ACLF,LTE4随ACLF分级和临床病程变化。
- LTE4、LXA5和EKODE与短期死亡率相关。
研究设计与样本
- 前瞻性研究,采用液相色谱-串联质谱法检测血浆脂质介质。
- 纳入急性失代偿期肝硬化伴ACLF(n=119)和不伴ACLF(n=127)患者及健康对照(n=18)。
- 对191例急性失代偿期肝硬化患者在28天随访期内重复测量。
主要发现
- 11种脂质介质可区分患者(任何阶段)与健康对照。
- LTE4和12-HHT(均衍生自花生四烯酸)组成最小血浆指纹区分ACLF与非ACLF。
- LTE4水平区分ACLF 3级与1、2级,随病情恶化升高、改善降低,与炎症标志物和非凋亡性细胞死亡正相关。
- LTE4联合LXA5(衍生自二十碳五烯酸)和EKODE(衍生自亚油酸)与短期死亡率相关;LXA5和EKODE形成与凝血和肝衰竭相关的特征。
临床怎么用
- 血浆脂质介质谱(尤其是LTE4、12-HHT、LXA5、EKODE)可能有助于评估急性失代偿期肝硬化患者的疾病严重程度和预后。
- LTE4动态变化可反映ACLF临床病程,辅助监测病情演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a newly described syndrome, which develops in patients with acute decompensation of cirrhosis, and is characterized by intense systemic inflammation, multiple organ failures and high short-term mortality. The profile of circulating lipid mediators, which are endogenous signaling molecules that play a major role in inflammation and immunity, is poorly characterized in ACLF. METHODS: In the current study, we assessed the profile of lipid mediators by liquid chromatography coupled to tandem mass spectrometry in plasma from patients with acute decompensation of cirrhosis, with (n = 119) and without (n = 127) ACLF, and from healthy controls (n = 18). Measurements were prospectively repeated in 191 patients with acute decompensation of cirrhosis during a 28-day follow-up period. RESULTS: Fifty-nine lipid mediators (out of 100) were detected in plasma from cirrhotic patients, of which 16 were significantly associated with disease status. Among these, 11 lipid mediators distinguished patients at any stage from healthy controls, whereas 2 lipid mediators (LTE4 and 12-HHT, both derived from arachidonic acid) shaped a minimal plasma fingerprint that discriminated patients with ACLF from those without. Levels of LTE4 distinguished ACLF grade 3 from ACLF grades 1 and 2, followed the clinical course of the disease (increased with worsening and decreased with improvement) and positively correlated with markers of inflammation and non-apoptotic cell death. Moreover, LTE4 together with LXA5 (derived from eicosapentaenoic acid) and EKODE (derived from linoleic acid) were associated with short-term mortality. LXA5 and EKODE formed a signature associated with coagulation and liver failures. CONCLUSION: Taken together, these findings uncover specific lipid mediator profiles associated with disease severity and prognosis in patients with acute decompensation of cirrhosis. LAY SUMMARY: Acute-on-chronic liver failure (ACLF) is characterized by intense systemic inflammation, multiple organ failures and high short-term mortality. In the current study, we assessed the plasma lipid profile of 100 bioactive lipid mediators in healthy controls, patients with decompensated cirrhosis, and those who had developed ACLF. We identified lipid mediator signatures associated with inflammation and non-apoptotic cell death that discriminate disease severity and evolution, short-term mortality and organ failures.
引用
- López-Vicario C, Checa A, Urdangarin A, et al. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. J Hepatol. 2020. PMID: 32294533. doi:10.1016/j.jhep.2020.03.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。